News

Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage

Annual General Meeting of Active Biotech AB

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

Annual Report 2021 Active Biotech AB (publ)

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Active Biotech Interim Report Q1 2022

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Aktiespararna: Analysis Active Biotech: “Breddad klinisk portfölj” (in Swedish)

Redeye: Analysis Active Biotech: Advancing Three Active Projects

Active Biotech: Year End Report 2021

Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma

Active Biotechs presentation at Aktiespararnas “Aktiedagen Lund” January 31, 2022

Active Biotech Appoints Erik Vahtola as Chief Medical Officer

Active Biotech’s nomination committee appointed

First subject dosed in phase I clinical study with eye-drop formulation of laquinimod

Data on naptumomab estafenatox enhancing CAR-T cells potency presented by Active Biotech’s partner NeoTX at SITC 2021

Aktiespararna: Analysis Active Biotech: “Effektsignal i fas 1” (in Swedish)

Active Biotech’s partner NeoTX to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

New preclinical data on tasquinimod will be presented at the annual meeting of American Society of Hematology (ASH)

Active Biotech Interim report January – September 2021

Active Biotech and NeoTX today announce that the first patient has been enrolled in the phase IIa clinical trial of naptumomab estafenatox in combination with docetaxel in patients with advanced non-small cell lung cancer (NSCLC)

Tasquinimod clinical development in multiple myeloma advances into combination therapy following completion of the initial phase of the ongoing trial in the US

Active Biotech presentation at Aktiespararnas “Aktiedag Lund” (in Swedish)

Analys Active Biotech: Ny plan för ögonstudie (in Swedish)

Active Biotech AB Interim report January – June 2021

Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance

Active Biotech provides status update of its clinical naptumomab project

Active Biotech: CEO Helen Tuvesson presents at Redeye Growth Day 2021 (Swedish)

Active Biotech’s presentation at ABGSC Life Science Summit May 25 2021

Annual General Meeting of Active Biotech AB

Active Biotech’s presentation at “Aktiedagen” May 4, 2021 (Swedish shareholders’ association, in Swedish)

Aktiespararna initiate coverage of Active Biotech

Annual Report 2020 Active Biotech AB (publ)

Active Biotech AB Interim report January – March 2021

ACTIVE BIOTECH: NOTICE of ANNUAL GENERAL MEETING OF SHAREHOLDERS

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Active Biotech’s presentation at Solebury Trout European Biotech Investor Days 2021

Number of shares and votes in Active Biotech

Number of shares and votes in Active Biotech

Active Biotech Year-end report January – December 2020

Active Biotech enters into a manufacturing agreement with Famar Health Care Services for new formulation of Laquinimod

Active Biotech’s rights issue heavily oversubscribed

Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue

Active Biotech publishes prospectus and certain new financial information included in the prospectus

Redeye initiates coverage of Active Biotech, see analysis

Active Biotech Receive Milestone Payment From NeoTX

Active Biotech’s presentation at Life Science Day 2020 (in Swedish)

Active Biotech’s nomination committee appointed

Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue